Research focus should remain on high quality studies during COVID-19 pandemic, say scientists
Exceptions to high quality research should not be made simply because of the COVID-19 pandemic, argue scientists in a new commentary.
List view / Grid view
News
EMA warns about side effects of chloroquine and hydroxychloroquine for COVID-19 treatment
The COVID-19 European Medicines Agency (EMA) pandemic Task Force (COVID-ETF) warned that chloroquine and hydroxychloroquine are yet to be proved effective at treating COVID-19 and that their side effects could be fatal.
Germany to begin first clinical trial of COVID-19 vaccine candidate
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
Novel antibody delivery method could improve precision medicine
Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.
UK COVID-19 vaccine candidate to be manufactured at seven outsourced sites
Following the initiation of a clinical trial, a COVID-19 vaccine candidate developed by UK researchers is being manufactured in several outsourced facilities.
Developing a COVID-19 biosensor for faster diagnostics and environmental monitoring
A team have developed a biosensor with high specificity and sensitivity for COVID-19 that could be used in hospitals, train stations or laboratories to detect SARS-CoV-2.
FDA accelerates approval of Trodelvy to treat triple-negative breast cancer
The US FDA has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy), to treat triple-negative breast cancer in adult patients.
SGS joins Oxford University consortium led by the Jenner Institute to develop COVID-19 vaccine
In a consortium led by the Jenner Institute, Oxford University, SGS has joined forces with specialists in infectious diseases, research and innovation, and pharmaceuticals to rapidly develop, scale-up and produce a potential vaccine called ChAdOx1 nCov-19.
FDA approves IMBRUVICA® (ibrutinib) for treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma
IMBRUVICA (ibrutinib), in combination with rituximab, has been given approval in the US for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma.
4D pharma to initiate Phase II study of MRx-4DP0004 to treat COVID-19
The UK MHRA granted expedited acceptance for the Phase II trial of MRx-4DP0004, a live biotherapy product and targeted immunomodulatory therapy.
Avet recalls tetracycline HCl capsules to consumer level
The company announced the voluntary recall is due to low, out of specification dissolution test results in specific batches of its tetracycline products.
CDMO recognised in six outsourcing award categories
A Contract Development and Manufacturing Organisation (CDMO) has been recognised in six different categories at the 2020 CMO Leadership Awards.
UK to begin clinical trials for COVID-19 vaccine this week
The UK government has announced that funding will be given to clinical trials to test a COVID-19 vaccine, with one study beginning tomorrow.
BARDA to give Moderna up to $483 million for COVID-19 vaccine development
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
Trial finds lopinavir/ritonavir and Arbidol ineffective for mild-to-moderate COVID-19
A Phase IV trial in 86 patients with mild-to-moderate COVID-19 has indicated that lopinavir/ritonavir (LPV/r) and Arbidol do not improve clinical outcomes.
